Cargando…

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

AIMS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced or preserved ejection fraction. In this study, the safety and efficacy of dapagliflozin according to background diuretic therapy and the influence of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatur, Safia, Vaduganathan, Muthiah, Claggett, Brian, Vardeny, Orly, Desai, Akshay S, Jhund, Pardeep S, de Boer, Rudolf A, Lam, Carolyn S P, Kosiborod, Mikhail N, Shah, Sanjiv J, Martinez, Felipe, Inzucchi, Silvio E, Hernandez, Adrian F, Haddad, Tariq, Mitter, Sumeet S, Miao, Zi Michael, Petersson, Magnus, Maria Langkilde, Anna, McMurray, John J V, Solomon, Scott D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Fast Track Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484057/ https://www.ncbi.nlm.nih.gov/pubmed/37220093 http://dx.doi.org/10.1093/eurheartj/ehad283

Ejemplares similares

Dapagliflozin for heart failure according to body mass index: the DELIVER trial( )
por: Adamson, Carly, et al.
Publicado: (2022)

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H, et al.
Publicado: (2023)

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021)

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
por: Yeoh, Su Ern, et al.
Publicado: (2023)

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation( )
por: Kondo, Toru, et al.
Publicado: (2022)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2022)

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Ostrominski, John W., et al.
Publicado: (2022)

Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
por: Chatur, Safia, et al.
Publicado: (2023)

Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial
por: Jhund, Pardeep S., et al.
Publicado: (2023)

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
por: Jhund, Pardeep S., et al.
Publicado: (2022)

Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER
por: Wang, Xiaowen, et al.
Publicado: (2022)

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial
por: Butt, Jawad H., et al.
Publicado: (2022)

Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial
por: Peikert, Alexander, et al.
Publicado: (2023)

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H., et al.
Publicado: (2023)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials
por: Clephas, Pascal R D, et al.
Publicado: (2023)

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial( )
por: Tardif, Jean Claude, et al.
Publicado: (2022)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER
por: Bhatt, Ankeet S., et al.
Publicado: (2023)

Anisotropic Isolation by Distance: The Main Orientations of Human Genetic Differentiation
por: Jay, Flora, et al.
Publicado: (2013)

Good Codons, Bad Transcript: Large Reductions in Gene Expression and Fitness Arising from Synonymous Mutations in a Key Enzyme
por: Agashe, Deepa, et al.
Publicado: (2013)

The Adaptation of Temperate Bacteriophages to Their Host Genomes
por: Bobay, Louis-Marie, et al.
Publicado: (2013)

MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
por: Katoh, Kazutaka, et al.
Publicado: (2013)

At the Transition from Invertebrates to Vertebrates, a Novel GnRH-Like Peptide Emerges in Amphioxus
por: Roch, Graeme J., et al.
Publicado: (2014)

Possible Loss of the Chloroplast Genome in the Parasitic Flowering Plant Rafflesia lagascae (Rafflesiaceae)
por: Molina, Jeanmaire, et al.
Publicado: (2014)

RetrogeneDB—A Database of Animal Retrogenes
por: Kabza, Michał, et al.
Publicado: (2014)

Patterns of Positive Selection in Seven Ant Genomes
por: Roux, Julien, et al.
Publicado: (2014)

An Experimentally Determined Evolutionary Model Dramatically Improves Phylogenetic Fit
por: Bloom, Jesse D.
Publicado: (2014)

Bears in a Forest of Gene Trees: Phylogenetic Inference Is Complicated by Incomplete Lineage Sorting and Gene Flow
por: Kutschera, Verena E., et al.
Publicado: (2014)

ExaBayes: Massively Parallel Bayesian Tree Inference for the Whole-Genome Era
por: Aberer, Andre J., et al.
Publicado: (2014)

Parallel Evolution of Tetrodotoxin Resistance in Three Voltage-Gated Sodium Channel Genes in the Garter Snake Thamnophis sirtalis
por: McGlothlin, Joel W., et al.
Publicado: (2014)

CodonPhyML: Fast Maximum Likelihood Phylogeny Estimation under Codon Substitution Models
por: Gil, Manuel, et al.
Publicado: (2013)

Comparative Genome Analysis and Gene Finding in Candida Species Using CGOB
por: Maguire, Sarah L., et al.
Publicado: (2013)

Insights into the Origin of Metazoan Filopodia and Microvilli
por: Sebé-Pedrós, Arnau, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nm0aplsb9n3hp8lhaokj2qha69